FORMULATION AND EVALUATION OF COLON SPECIFIC DRUG DELIVERY OF BUDESONIDE
The purpose of this study was made to treat ulcerative colitis (UC) and to improve the patient compliance by developing a colon targeted drug delivery of budesonide. Budesonide were selected as model standard drugs to treat UC. Budesonide is a potent, synthetic non-halogenated corticosteroid with high topical anti-inflammatory effect and little systemic effects. Tablets were prepared by wet granulation method using HPMC K4M and Eudragit L30D coating for the sustained release in the entire colon region. All the formulations (S1-S15) were evaluated for different physicochemical characteristics like thickness and diameter, drug content, weight variation, hardness and friability. The release characteristics of formulations were studied in in vitro condition. The results of the study showed that formulation S15 was proved to be good drug content, dimensional stability, lag time and drug release in the colonic region as compared to the other formulations. Stability studies were carried out on the optimized formulation S15 for period of 3 months at 400c/75 %RH as per ICH guidelines. It showed that no significant changes in the physiochemical parameters, as well as in vitro release pattern